Briefing
DETECTION-2 is testing ctDNA monitoring against immediate adjuvant therapy in resected stage II and IIIA melanoma
A 2025 methods report describes DETECTION-2 (ISRCTN13695430), a feasibility randomization of patients with resected stage IIB, IIC, or IIIA melanoma to standard adjuvant therapy or to ctDNA monitoring with treatment if ctDNA is detected, and states that eight UK sites opened between November 27 and December 23, 2024.